Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MTX pathway gene variants, erythrocyte methotrexate polyglutamates, and treatment outcomes in rheumatoid arthritis.

Biomolecules & biomedicine - 19 Jan 2026

Wang Peihong, Liang Cuilv, Lin Limei, Lan Jieli, Zhang Yin, Xie Weiping

Abstract excerpt

Rheumatoid arthritis (RA) exhibits significant inter-patient variability in response to and toxicity from methotrexate (MTX). The clinical utility of erythrocyte methotrexate polyglutamates (MTXPGs) and MTX-pathway pharmacogenetics remains uncertain. This study investigates the relationships between MTX-pathway gene polymorphisms, erythrocyte MTXPG levels, and MTX treatment outcomes in RA. In a single-center,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antirheumatic Agents
Share to Arthritis, Rheumatoid

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cross-Sectional Studies

Share to Erythrocytes

Share to Liver-Specific Organic Anion Transporter 1

Share to Methotrexate

Share to Polymorphism, Single Nucleotide

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 41554112
DOI: 10.17305/bb.2026.13544
PMCID: PMC13021033

Genes

SLCO1B1
ABCB1
GGH

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MTX pathway gene variants, erythrocyte methotrexate polyglutamates, and treatment outcomes in rheumatoid arthritis.PMID 41554112Read ↗

Methotrexate pharmacogenetics in rheumatoid arthritis: a status report.Semantic proximity Read ↗

Role of methotrexate polyglutamation and reduced folate carrier 1 (RFC1) gene polymorphisms in clinical assessment indexes.Semantic proximity Read ↗

Using pharmacogenetics to predict methotrexate response in rheumatoid arthritis patients.Semantic proximity Read ↗

Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis.Semantic proximity Read ↗

Genetic polymorphisms associated with therapeutic response and adverse effects to methotrexate in Taiwanese patients with rheumatoid arthritis: a real-world, hospital-based study.Semantic proximity Read ↗

Association of folylpolyglutamate synthase polymorphisms with methotrexate response and toxicity in rheumatoid arthritis: a meta-analysis.Semantic proximity Read ↗

Moving toward personalized medicine in rheumatoid arthritis: SNPs in methotrexate intracellular pathways are associated with methotrexate therapeutic outcome.Semantic proximity Read ↗

Effect of Genetic Polymorphisms in the Folate Pathway on Methotrexate Therapy in Rheumatic DiseasesSemantic proximity Read ↗

Influence of FPGS rs1544105 and GGH rs3758149 Gene Polymorphisms on Methotrexate Pharmacogenetics.Semantic proximity Read ↗

Factors Underlying Failure of Methotrexate Treatment in Rheumatoid Arthritis: Implications in Personalized CareSemantic proximity Read ↗

The pharmacogenetics of methotrexateSemantic proximity Read ↗

Pharmacogenomics of Methotrexate Membrane Transport Pathway: Can Clinical Response to Methotrexate in Rheumatoid Arthritis Be Predicted?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.